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Summary Many recent studies have implicated p53 in the cellular response to injury and induction of cell
death by apoptosis. In a rat embryonal fibroblast cell line transformed with c-Ha-ras and a mutant
temperature-sensitive p53 (val135), cells were GI arrested at the permissive temperature of 32°C when
overexpressed p53 was in wild-type conformation. In this state cells were resistant to apoptosis induced by
etoposide (at up to 5011M) or bleomycin (15;LU ml-'). Cells at 37°C with overexpressed p53 in mutant
conformation were freed from this growth arrest, continued proliferating and showed dose-dependent increases
in apoptosis. This death is independent of wild-type p53 function. Control cells containing a non-temperature-
sensitive mutant p53 (phel32) were sensitive to both etoposide and bleomycin after 24 h at 32°C and 37°C,
indicating that the results are not simply due to temperature effects on pharmacokinetics or IINA damage.
Our data show that induction of a stable p53-mediated growth arrest renders these cells much less likely to
undergo apoptosis in response to certain anti-cancer drugs, and we conclude that the regulatory role of p53 in
apoptosis is influenced by the particular cellular context in which this gene is expressed.
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Many tumours are resistant to chemotherapy, either intrinsic-
ally or following an initial partial response. A number of
pharmacokinetic explanations may account for this, including
overexpression of the multidrug resistance gene mdrl, overex-
pression of drug detoxication enzymes, or alteration of the
drug target, for example topoisomerase II isoform. However
despite intensive study of drug-target interactions, and drug
metabolism, it is clear that in many instances drug resistance
is associated with a failure of induction of apoptosis, even
after an appropriate triggering event. Since many anti-cancer
drugs and ionising radiation damage DNA, the response of
the cell in recognising injury and proceeding to repair or
apoptosis is of paramount importance (Hickman, 1992; Har-
rison, 1995).
Entry to apoptosis is regulated by a number of genes (see
Bellamy et al., 1995 for general review), each of which may
show abnormal expression or function in cancer. In Rat-I
fibroblasts cell cycle arrest or serum deprivation in the
presence ofconstitutive expression ofthe c-myc oncogene can
cause apoptosis (Evan et al., 1992). By contrast, overexpress-
ion of bcl-2 directly inhibits apoptosis in both normal and
neoplastic cells (Hockenberry et al., 1990; Sentman et al.,
1991; Miyashita and Reed, 1992, 1993; Veis et al., 1993) and
prevents c-myc-driven apoptosis (Wagner et al., 1993). More
recently evidence has accumulated implicating the tumour-
suppressor gene p53 in an injury-response pathway leading to
apoptosis. Thymocytes and myeloid progenitor cells from
p53 knockout mice, fail to undergo induced apoptosis in the
absence of a wild-type p53 allele following etoposide or
ionising radiation treatment but not apoptosis associated
with ageing in vitro or non-clastogenic insults such as dex-
amethasone treatment. (Clarke et al., 1993; Lotem and Sachs,
1993; Lowe et al., 1993a). Furthermore overexpression of
wild-type p53 in a variety of cancer-derived cell lines such as
Ml myeloid leukaemia (Yonish-Rouach et al., 1991), murine
erythroleukaemia (Ryan et al., 1993) and HT29 colon car-
cinoma (Shaw et al., 1992) resulted in an increase in spon-
taneous apoptosis.
By contrast, studies of p53 null fibroblasts grown in
primary culture have failed to detect alteration in cell sur-
vival characteristics after DNA damage as compared with
normal primary fibroblasts (Slichenmeyer et al., 1993). In the
latter experiments, cells were isogenic apart from p53 status.
This suggests that other factors, including cell lineage and
expression of oncogenes may modulate the effects of p53 on
cellular physiology. In both experimental and human tumori-
genesis p53 inactivation is believed to be a late event and is
therefore superimposed on a series of progressive genetic
abnormalities, such as activation of ras oncogenes (Fearon
and Vogelstein, 1990).
In this study we have used a rat embryonal fibroblast line
(Clone 6) transformed with activated Ha-ras and a temper-
ature-sensitive p53 mutant as a model of the role of p53 in
anti-cancer drug therapy in the presence of other genetic
alterations. We report that induction by wild-type p53 of a
GI arrest protects Clone 6 cells from apoptosis caused by the
anti-cancer drugs etoposide and bleomycin. Our data imply
that wild-type p53 provides a mechanism ofresistance ofcells
to chemotherapy but by allowing continued proliferation p53
mutations may nonetheless contribute to the development of
drug resistance.
Materials and methods
Clone 6 cells and RcGphe132.4 cells
Clone 6 cells are rat embryonic fibroblasts constitutively
expressing a human mutationally activated c-Ha-rasl gene
and a murine, temperature-sensitive p53 mutant, p53vall35.
At the permissive temperature of 32°C the p53 protein is
found predominantly in wild-type configuration but at 37.5°C
it adopts mutant conformation and function (Michalovitz et
al., 1990). RcGphel32.4 cells contain a temperature-stable
p53phel32 mutation in addition to activated c-Ha-rasl. The
level of p53 expression in these two cell lines is similar. All
manipulation of cell lines and counting was performed at the
selected temperature to minimise the risk of inadvertent p53
conformational shifts.
Cell culture
Cells were plated in duplicate flasks at a density of 2 x I04
cellscm2 in Glasgow modified Eagle's medium (GMEM)
supplemented with 10% fetal bovine serum (FBS) and
antibiotics.
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Reference points (three per flask) were used to count directly
the number of cells in x 100 field using a 10 x 10 graticule.
This permitted sequential counts at 20, 28 and 42 h after
plating at 32°C or 37°C. Apoptotic cells adherent to the
monolayer were counted at each time point as well as cell
number. The apoptotic cells were recognised by virtue of
their spherical, highly refractile appearance under phase con-
trast. These cells showed the classical appearances of apop-
tosis and were confirmed by electron microscopy and acridine
orange fluorescence microscopy (Arends and Harrison, 1994).
Effects ofbleomycin andetoposide
Twenty four hours after plating at 37°C cells were either
moved to a 32°C incubator or maintained at 37°C for a
further 16 h. Etoposide (10, 50 1M) or bleomycin sulphate
(15pUml-': 1 U = 1 mg bleomycin A2) were added for 1 h
and then washed with phosphate buffered saline (PBS). Cont-
rols were performed using equal concentrations of dimethyl
sulphoxide (DMSO) or PBS vehicles.
The number of viable and apoptotic cells was counted at
intervals up to 50h following drug treatment. The mean
number of apoptotic bodies per field was expressed as a
percentage of the mean adherent cell number ('percentage
apoptosis'). RcGphel32.4 cells were counted 24 h after drug
treatment.
Cell cycle analysis
Nuclei were isolated and stained with propidium iodide
(Vindelov et al., 1983), and 1 x 104 cells were analysed on an
EPICS CS flow cytometry (Coulter). Histogram analysis was
performed using the Easy 2 Software. No doublets were seen.
Bromodeoxyuridine incorporation analysis was carried out
using the Amersham Cell Proliferation Kit (cat no. RPN20).
Results
Clone 6 cells are growth arrested at 32°C
Exponentially growing cells were shifted to a 32°C incubator.
In three independent experiments cells ceased to show inc-
rease in cell number at 32°C (Figure 1). There was no inc-
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Figure 1 Growth properties of Clone 6 cells at 37°C (-) and at
32°C (0). Each point represents the mean number of cells per
field (n = 3) in one flask at each time point. Note that the cells
incubated at 32°C do not increase in number consistent with a wt
p53-induced growth arrest.
p53 and cell death in fibroblasts
RDG Malcomson etal
953
rease in apoptosis in the presence of p53 with wild-type
configuration (see Figure 2 controls). At 37°C, with mutant
conformation p53 there was a 3-fold increase in cell number
over the same period, confirming the original observations of
Michalovitz et al. (1990). DNA flow cytometry showed both
diploid and tetraploid peaks at permissive and non-perm-
issive temperatures. At 32°C there was in increase in the
diploid GO/, peak (Figure 3), and cells did not take up
bromodeoxyuridine consistent with this state (data not
shown). This growth arrest was reversible by transferring
cells to 37°C, even after 2 weeks, or more. By contrast
RcGphel32.4 cells continued to grow at a slightly reduced
rate at 32°C in keeping with the previous observations of
Michalovitz et al. (1990).
Clone 6 cells with wild typep53 are resistant to both etoposide
andbleomycin
At 37°C, in the presence of mutant conformation p53, there
was a progressive increase in apoptosis starting 6-1Oh after
pulsing with drug (Figure 2). The increase was dose depen-
dent: etoposide at 10gM induced a maximum of 6% apop-
tosis whereas at 50iLM the maximum was greater than 30%
apoptosis (Figure 4). By contrast, cells maintained at 32°C
with p53 in the wild-type conformation showed no increase
in percentage apoptosis, nor in cell number (Figures 2 and 4).
Treatment with bleomycin showed similar effects (Figure 5).
RcGphel32.4 cells are sensitive to apoptosis induced by
etoposide and bleomycin at 32°C and 37°C. We considered
the possibility that these differences in cell proliferation and
apoptosis in response to DNA damage might be due simply
to altered pharmacokinetics at the different temperatures.
The RcGphel32.4 cell line was derived from the same paren-
tal stock as Clone 6, but contains a temperature-insensitive
mutant p53; hence in this cell line wild-type p53 is excluded
from function at both 32°C and 37°C. At 37°C Clone 6 and
RcGphel32.4 cells show closely similar entry into apoptosis:
24 h after treatment with 50pM etoposide the incidences were
18.0% and 19.4% respectively. In contrast, at 32°C the
incidence of apoptosis in RcGphel32.4 cells was 9.5%, but
had fallen to less than 2% in Clone 6 cells. Very similar
results were obtained following treatment with bleomycin. At
37°C incidence of apoptosis in Clone 6 cells was 19.8%, but
fell to less than 3% at 32°C. In contrast, RcGphel32.4 cells
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Figure 2 Treatment of Clone 6 cells with 10 JM etoposide at
37°C (0) for I h results in substantial apoptosis, where as treated
cells at 32°C (-) and untreated controls (unfilled symbols) do not
show this increase. Note the latent period during induction of
apoptosis at 37°C. Each line represents a separate experiment
(performed in triplicate and expressed as a mean, for low values
the range was less than 0.6% and for higher value the range was
up to 2%).
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showed 10.3% apoptosis at 37°C and 8.9% at 32°C. Thus the
profound inhibition of apoptosis in Clone 6 cells at 32°C is
dependent upon the altered configuration of p53 to wild-type
and is not explicable solely on the basis of temperature
effects on pharmacokinetics.
Discussion
Expression of wt p53 has been shown to induce apoptosis in
some cell types (Yonish-Rouach et al., 1991; Shaw et al.,
a
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1992; Ryan et al., 1993), GI arrest and survival in others
(Baker et al., 1990; Diller et al., 1990; Mercer et al., 1990;
Michalovitz et al., 1990; Kastan et al., 1991; Kuerbitz et al.,
1992). In addition, wt p53 has been shown to be an essential
intermediate in a signal transduction pathway between the
effects of DNA damaging agents (DNA strand breaks) and
either apoptosis or GI arrest (Kastan et al., 1992; Kuerbitz et
al., 1992; Clarke et al., 1993; Lowe et al., 1993a). In this way
p53 seems to play a critical role in deleting certain cell types
that have sustained DNA damage e.g. thymocytes (Clarke et
al., 1993), lymphocytes (Gottlieb et al., 1994; Howie et al.,
b
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Figure 3 Cell cycle analysis of Clone 6 cells. (a) Exponentially growing cells at 37°C, untreated (GO/GI fraction: 46.56%). (b)
Following incubation at 32°C for 24 h, the GO/GI peak is enlarged (72.51%) and there is a marked decrease in the proportion of
cells between the GO/GI and G2/M peaks (S-phase). (c) At 37°C, 24 h after etoposide treatment (50gM) cells accumulated in G2/M
with only 10.18% of cells occupying the GO/GI position. (d) At 32°C, 24 h after treatment with 50gM etoposide (GO/GI fraction:
38.51%). Abcissa; DNA content (propidium iodide fluorescence).
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Figure 4 Treatment of Clone 6 cells with 50I1M etoposide for
1 h induces substantial apoptosis when cells are incubated at 37°C
(-). At 32°C treated cells (U) and in control cells treated with an
equivalent volume of DMSO vehicle (unfilled symbols) do not
show an increase in percentage apoptosis. Each line represents a
separate experiment (performed in triplicate and expressed as a
mean. For low values range was 2% and for high values was up
to 22%).
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Figure 5 Clone 6 cells treated with 15 Uml1 bleomycin sul-
phate for 1 h at 37°C (l) and at 32°C (U). Note that treated
cells incubated at 37°C undergo substantial apoptosis whereas
treated cells at 32°C and untreated controls (open symbols) do
not shown an increase in percentage apoptosis. Each line
represents a separate experiment (performed in triplicate and
expressed as a mean. For low values range was 2% and for high
values range was up to 12%).
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(Lotem and Sachs, 1993) or in establishing a state of GI
arrest, possibly permitting DNA repair (Lane, 1993; Bakalkin
et al., 1994). Clearly the cellular context in which p53 is
expressed is important. Murine fibroblasts or primary rat
kidney cells can be induced to undergo apoptosis by p53 in
response to disruption of growth control by coexpression of
c-myc (Wagner et al., 1994) or adenovirus EIA (Debbas and
White, 1993) respectively.
The finding that p53 function is lost in many authentic
human and experimentally induced animal tumours has led
to the assumption that p53 loss of function is causally
associated with resistance to anti-cancer therapy (Lowe et al.,
1993b). In this study we have addressed the importance of
p53 status on the sensitivity of cells to apoptosis induced by
two anti-cancer drugs.
We have shown here, in a fibroblast cellTine transformed
with activated Ha-ras and temperature-sensitive p53 trans-
genes that wild-type p53 leads to GI arrest and at the same
time resistance to the DNA damaging agents bleomycin and
etoposide. By contrast, in the presence of mutant conforma-
tion p53, cells underwent apoptosis associated with a relative
accumulation in G2/M, a common response to DNA injury
in yeast and mammalian cells (Hartwell and Weinert, 1989).
We were unable to produce a GO/GI arrest in Clone 6 cells at
37°C by either mimosine treatment or serum starvation as
these treatments caused the death of the cultures. We were
thus unable to show directly that a growth arrest in GO/GI,
independent of p53, was protective against DNA damage.
Our findings apparently contrast with published work in
which temperature-sensitive p53 was expressed in the Ml
myeloid leukaemic (Ml; Yonish-Rouach et al.,1993) and
murine erythroleukaemic (MEL; Ryan et al., 1993) cell lines
induced apoptosis upon incubation at 32°C (i.e. with wild-
type p53). MEL cells underwent GI arrest before undergoing
apoptosis, but in M 1 cells, no growth arrest could be
observed at any position in the cell cycle. In addition, other
cell types (including rat fibroblasts) have been shown to
undergo GI arrest but not apoptosis in response to wild-type
p53 induction (Diller et al., 1990; Mercer et al., 1990;
Michalovitz et al., 1990; Kastan et al., 1992). While
bleomycin and etoposide maximally kill cells in S-phase,
where replication forks are forced to negotiate either cleaved
complex / double strand breaks (etoposide; Bae et al., 1988)
or double-strand breaks resulting from free-radical attack
(bleomycin; Kuo, 1981), they can damage and kill cells in
GO/GI (Roy et al., 1992; Clarke et al., 1993; Evans et al.,
1994). In cell lines derived from clinically sensitive human
tumours, DNA injury-induced wild-type p53 was held to be
responsible for decreased clonogenicity following ionising
radiation and this effect could be reversed by transfection of
a dominant negative mutant p53. (McIlwrath et al., 1994).
The simplest explanation of our data is that the GI arrest
mediated by p53 facilitates survival of ras-transformed fibro-
blasts by allowing effective DNA repair and prevents entry
into S-phase, a stage when cells are often most susceptible to
DNA damage.
Depending upon the cell system chosen, induction of p53
can cause either GI arrest, apoptosis or both apoptosis and
GI arrest (Michalovitz et al., 1990; Debbas and White, 1993;
Ryan et al., 1993; Yonish-Rouach et al., 1993; Wu and
Levine, 1994). The mechanisms by which decisions are taken
that favour any of these end points are poorly defined but
these decisions can be affected by specific growth factors
(Yonish-Rouach et al., 1991; Gottleib et al., 1994; Canman et
al., 1995). In particular, it is not known how p53 can mediate
apoptosis in the thymocyte but not in the fibroblast. The
recognition of DNA damage (possibly involving the ataxia
telangiectasia gene products; Kastan et al., 1992) leads, via
p53, to the control of the cell cycle at the GI checkpoint. We
have shown this pathway to be protective in fibroblasts. Our
results complement those of Lowe et al. (1993b) who showed
that p53-normal fibroblasts were susceptible to anti-cancer
treatment as a result of abrogation of the p53-mediated GI
arrest by adenovirus EIA expression. Further, interleukin 6
(IL6) protects Ml cells from undergoing p53-mediated cell
death (Yonish-Rouach et al., 1991, 1993) and this protection
also correlates with the induction of a GO/GI arrest. (Levy et
al., 1993).
Wafl (Cipl / sidl, p21), a gene product which is induced
by wt p53, has potent inhibitory activity on cyclin E / cdk2
complexes in cells undergoing radiation-induced GI arrest
(El-Deiry et al., 1993, 1994; Dulic et al., 1994). Wafl is
therefore a major regulator of cell cycle progression at the
G,/S interface. The expression of Wafl in cell types that
undergo apoptosis following activation of the p53 pathway
suggests that it may be active in both arrest and death
mechanisms. The decision of a cell to die may therefore be
determined by other lineage-dependent messages or growth
factors (Canman et al., 1995), although the activity of Wajl
as an apoptosis-inducing gene has not yet been directly
tested. One such determinant may be the level of activity of
the transcriptional regulator E2F-1. When constitutively
overexpressed in the presence of wild-type p53 this triggers
death in fibroblasts (Wu and Levine, 1994).
Using a different mutated p53 (proline substituted at
residue 193) under its physiological promoter, Bristow et al.
(1994) have recently shown that co-transfection of activated
Ha-ras and mutated p53 into a primary rat embryonal fibro-
blast cell line resulted in enhanced clonogenicity in vitro and
tumorigenicity in severe combined immunodeficient (SCID)
mice after irradiation compared with cell lines containing ras
alone. This effect was dependent on the level of mutant p53
expression, presumably as a result of competition with
endogenous wild-type p53. However they did not directly
assess the proportion of cells undergoing proliferation,
growth arrest or cell death. We could not carry out
experiments similar to those of Bristow et al. (1994) with
ionising radiation sources as we found that reproducibility of
results could not be maintained if there were fluctuations in
temperature of Clone 6 cells before or during experiments.
Indeed, clonogenicity of Clone 6 at 32°C is negligible.
Our in vitro experiments with DNA-damaging drugs (inc-
luding the radiomimetic bleomycin) show that, under certain
circumstances, overexpression of wild-type p53 can protect a
cell which has suffered DNA injury against death rather than
kill it, by causing cell growth to arrest in GI. The corollary in
vivo is that wild-type p53 in an appropriate cellular context
could confer a state of increased drug resistance. The
significance of mutated p53 oncosuppressor gene in clinical
drug resistance is likely to be both complex and variable
depending on the existence of other pathways of cell cycle
activity control and response to injury. We show here that
death of fibroblasts induced by etoposide and bleomycin
occurs independently of wild-type p53 function. This
confirms work by Strasser et al. (1994) which showed that
thymic lymphoma cells from p53 - / - mice underwent apop-
tosis by p53-independent mechanisms following irradiation.
Tumours which contain cells with mutated p53 initially may
be more susceptible to cell death caused by therapy. However
in the absence of GI arrest caused by wild-type p53, and
therefore in the presence of continuing cell cycle activity,
combined with karyotype instability (Livingstone et al., 1992;
Yin et al., 1992), clones resistant to therapy may appear thus
conferring a clinical state of 'drug-resistant' disease.
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